NexOptic Announces Private Placement

In This Article:

VANCOUVER, BC / ACCESSWIRE / November 7, 2024 / NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE:NXO)(OTCQB:NXOPF)(FSE:E3O1), a company developing cutting-edge AI and imaging technologies, is pleased to announce that, further to its news release dated October 24, 2024, it intends to complete a non-brokered private placement of up to 28,571,428 units (each, a "Unit") of the Company, at a price of $0.035 per Unit, for gross proceeds of up to $1,000,000 (the "Offering").

Each Unit will be comprised of one common share in the capital of NexOptic (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant will be exercisable for one Common Share at a price of $0.05 per Common Share, for a period of eighteen (18) months from the date of issuance. The Warrants are subject to accelerated exercise provisions such that if the closing price of the Company's common shares exceeds $0.12 per share for a period of 10 consecutive trading days, the Company may, at its discretion give notice of the acceleration of the warrants' term to a period of 15 days following such notice. Enquiries can be directed to envision@nexoptic.com

In the continuation of streamlining its operations, NexOptic has opted to discontinue its affiliations with several third-party companies including semiconductor companies. The Company may reassess these relationships in the future. Additional cost saving decisions include closing the Company's Korean subsidiary, NexOptic Asia. The new direction of NexOptic will be to leverage its success in an FDA approved medical imaging device that significantly increases image resolution. Enhancements to NexOptic's AI compression offering, NexCompress, is also planned. NexCompress can offer significant cost and energy savings to the security camera and video streaming industries. Announcements related to sales and marketing appointments and product advancements are anticipated by the Company. Please see additional details on the Company's go forward plans in the "Corporate Update" section of the Company's news release dated October 24, 2024.

NexOptic intends to use the proceeds from the Offering to advance its data compression and video resolution artificial intelligence ("AI") and its medical imaging enhancement software technologies, marketing and sale of the Company's products, investor relations, and for general corporate working capital purposes, including any current working capital deficiencies. The Company expects to allocate the net proceeds of the Offering equally to the foregoing uses, other than with respect to investor relations activity, which will be limited to 10% of the proceeds of the Offering in accordance with TSX Venture Exchange ("TSXV") policies. The Company does not intend to use the proceeds of the Offering to pay any Non-Arm's Length Parties (as defined in TSXV Policies) of the Company, other than loan repayments and compensation payable to management in the normal course.